ASX-listed Telix rises on Varian tie-up to pair theranostic drugs with radiation therapy

ASX-listed shares of Telix Pharmaceuticals TLX.AX advance as much as 4.29% to A$14.6, their biggest intraday pct gain since December 4

The drugmaker inks a clinical collaboration with U.S.-based Varian to explore new applications combining its theranostic products with external beam radiation therapy

External beam radiation therapy remains a proven, widely used option for most solid tumours

Stock down 42.67% so far this year